TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Earnings Deep Dive·November 2, 2026

IDEXX Laboratories, Inc. (IDXX) spikes on deep earnings beat

IDEXX Laboratories, Inc. (IDXX) spiked after a strong Q3 beat, margin expansion, and raised 2026 guidance. This deep-dive looks beyond the headline, breaking down recurring diagnostics growth, international momentum, premium instrument placements, cash flow strength, and what the results may mean for the stock.

Earnings Deep DiveIDXXHealthcareMedical - Diagnostics & Research
By TickerSpark·November 2, 2026·6 min read
IDEXX Laboratories, Inc. (IDXX) spikes on deep earnings beat
▌Key Takeaway
IDEXX Laboratories (NASDAQ: IDXX) delivered a strong Q3 earnings beat, with EPS of $3.96 topping estimates by $0.23 and revenue of $1.21 billion also ahead of consensus. The company raised 2026 guidance, and investors responded with a 20.24% share-price jump as recurring diagnostics growth, margin expansion, and premium instrument placements reinforced the bullish case.

IDEXX Laboratories, Inc. (IDXX) spikes after a strong Q3 earnings beat and higher 2026 guidance. EPS reached $3.96 versus the $3.73 estimate, while revenue came in at $1.21B against $1.19B expected. By 14:30 ET on Nov. 2, shares had gained 20.24% to $662.78 on volume well above average.

Key Takeaways

  • IDXX posted Q3 EPS of $3.96, beating consensus by $0.23. Revenue of $1.21B also topped the $1.19B estimate.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Organic revenue grew 10%, led by 11% organic growth in companion animal diagnostics recurring revenue.
  • International companion animal diagnostics recurring revenue grew 14%, while US growth reached 9.6% despite a 1.8% decline in same-store clinical visits.
  • Management raised 2026 revenue guidance to $4.741B-$4.767B and EPS guidance to $14.96-$15.16.
  • The company placed 5,780 premium instruments, including 1,904 inVue Dx analyzers, reinforcing the role of new products in growth.
  • Analyst sentiment remains constructive. The listed consensus includes 13 Buy ratings, 9 Holds, and 1 Sell, although several firms reduced price targets.
  • IDXX Financial Performance: Diagnostics Drives the Beat

    The central result in this IDEXX Laboratories, Inc. earnings analysis is the combination of growth and operating leverage. Q3 revenue reached $1.21B, up from $1.11B in the year-ago quarter. Revenue was slightly below the prior quarter's $1.22B, but EPS remained well above the year-ago level of $3.40.

    EPS of $3.96 also marked the fifth straight period in the listed earnings history where IDXX exceeded its estimate. The prior quarter produced EPS of $4.27, so the sequential comparison softened. However, the year-over-year improvement remains substantial, and the current result cleared the $3.73 consensus estimate by $0.23.

    Companion animal diagnostics remained the engine. CAG revenue grew 10% organically, with recurring diagnostics revenue up 11%. US recurring revenue increased 9.6%, supported by greater testing frequency and broader testing intensity per visit. International recurring revenue grew 14%, with double-digit gains across major regions.

    The segment mix was broad rather than dependent on one product. IDEXX VetLab consumables grew 15% organically. Reference laboratory revenue increased 10%, while veterinary software and diagnostic imaging also grew 10%. Water revenue rose 8%, livestock, poultry, and dairy revenue advanced 3%, and rapid assay revenue increased 1%.

    That performance translated into stronger margins. Reported operating margin reached 33.1%, an increase of 100 basis points. Comparable operating margin improved by about 60 basis points, even with costs tied to the CoVet acquisition. Gross margin rose 110 basis points to 62.9%, or 90 basis points on a comparable basis.

    Management attributed the margin gains to recurring revenue growth, higher RefLab volumes, productivity, favorable mix, and pricing that offset inflationary costs. Q3 free cash flow reached $421M, bringing the year-to-date total to $978M. Trailing 12-month net income to free cash flow conversion stood at 110%.

    The CoVet acquisition adds a newer growth layer. CoVet carries an annualized revenue run rate of about $20M and is growing at double-digit rates. Still, the deal creates near-term dilution of about $0.13 per share in the full-year outlook. That tradeoff matters because IDXX is funding software and artificial intelligence expansion while protecting its core diagnostics engine.

    Market Reaction and Analyst Response

    The stock reaction was decisive. IDXX opened at $551.21 and reached $662.78 by 14:30 ET on Nov. 2. The 20.24% gain came with 1,404,461 shares traded, compared with an average volume of 553,104. In plain English, investors treated the beat and guidance increase as a reset of near-term expectations.

    Analyst actions were more measured than the share-price move. JPMorgan maintained Overweight but cut its target from $775 to $750. Barclays also kept Overweight while reducing its target from $800 to $710. Jefferies maintained Buy and lowered its target from $795 to $705, while Leerink Partners kept Outperform and reduced its target from $725 to $715.

    There were also constructive changes. Citigroup maintained Neutral but raised its target from $650 to $670. Overall, the listed actions point to target recalibration rather than a broad shift toward bearish ratings. The consensus remains Buy, with 13 Buy ratings, 9 Holds, and 1 Sell.

    That split between a sharp stock move and lower targets is worth noting. Analysts accepted the operating strength, but several still applied a more cautious valuation framework. Strong results can improve the business while making the stock harder to underwrite after a large rally. Markets are occasionally capable of appreciating both facts at once.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Management Commentary: Innovation, Utilization, and Guidance

    CEO Mike Erickson framed the quarter as a broad execution story. His focus was not limited to instrument placements. He emphasized the way point-of-care diagnostics, reference laboratories, and software reinforce one another.

    "IDEXX delivered an exceptional third quarter, driven by execution across all growth drivers, expansion of diagnostic utilization, growth in our global instrument and customer base, and continued delivery against our broad-based innovation pipeline." - Mike Erickson, CEO, earnings call

    Erickson's strategic point is important. US same-store clinical visits fell 1.8%, yet recurring diagnostics revenue grew 9.6%. Management said pets aged five years and older contributed to clinical visit growth, while most wellness visits still exclude blood work. That leaves a large utilization opportunity that does not depend entirely on more clinic visits.

    CFO Andrew Emerson supplied the financial bridge. He highlighted organic growth, premium instrument placements, and the effect of IDEXX Innovations on recurring revenue.

    "Revenue increased 10% organically, supported by 11% organic growth in CAG Diagnostics recurring revenues." - Andrew Emerson, CFO, earnings call

    Emerson raised full-year revenue guidance by $32M at the midpoint. The new range implies overall organic revenue growth of 9.3%-10%, including 10.3%-11% growth in CAG Diagnostics recurring revenue. Global net price realization contributes about 4% to that recurring revenue outlook.

    "We expect to expand margin off of these levels over the next 12 months, aligned with our long-term goals." - Andrew Emerson, CFO, earnings call

    The financial guidance also includes a 2026 operating margin range of 32.1%-32.3% and EPS of $14.96-$15.16. CoVet creates about 30 basis points of negative margin impact, while lower interest expense, a lower effective tax rate, and share repurchases support EPS. The company expects a 2% reduction in average diluted shares outstanding.

    Bottom Line

    This IDXX earnings call showed a business still converting innovation into recurring revenue, even as US clinic visits weakened. Higher guidance, 33.1% operating margin, and strong instrument placements support the growth case, while reduced analyst targets and CoVet dilution keep valuation discipline central to the investment decision.

    Read the full IDXX research report
    ▌Common Questions

    Frequently asked questions

    +Why did IDEXX Laboratories stock jump after earnings?
    IDEXX Laboratories (IDXX) surged after reporting Q3 EPS of $3.96 versus the $3.73 estimate and revenue of $1.21 billion versus $1.19 billion expected. The company also raised 2026 guidance, which signaled stronger-than-expected business momentum and helped drive a 20.24% stock gain.
    +What were IDEXX's Q3 2026 earnings and revenue results?
    IDEXX reported Q3 EPS of $3.96, beating consensus by $0.23. Revenue came in at $1.21 billion, above the $1.19 billion estimate and up from $1.11 billion a year earlier.
    +How much did IDEXX raise its 2026 guidance?
    IDEXX raised 2026 revenue guidance to $4.741 billion-$4.767 billion and EPS guidance to $14.96-$15.16. Management also noted about $0.13 per share of full-year dilution from the CoVet acquisition.
    +What drove IDEXX's growth in the quarter?
    Companion animal diagnostics was the main driver, with organic revenue up 10% and recurring diagnostics revenue up 11%. International recurring revenue grew 14%, U.S. recurring revenue rose 9.6%, and the company placed 5,780 premium instruments, including 1,904 inVue Dx analyzers.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on IDXX?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the IDXX report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full IDXX research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the IDXX report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on IDXX

    More to read

    All articles
    IDEXX Laboratories (IDXX): Premium Diagnostics, Rich Valuation
    IDXX

    IDEXX Laboratories (IDXX): Premium Diagnostics, Rich Valuation

    IDEXX posted double-digit Q3 growth and raised full-year guidance, but the stock already prices in much of that strength. Our stance is Hold with a fair value of $690.

    Nov 2·21 min
    IDEXX Laboratories, Inc. (IDXX) jumps 19% on earnings
    IDXX

    IDEXX Laboratories, Inc. (IDXX) jumps 19% on earnings

    IDEXX Laboratories, Inc. (IDXX) jumps after a strong Q3 report and higher full-year guidance. The veterinary diagnostics leader beat earnings estimates, posted double-digit revenue growth, and raised its 2026 outlook, fueling a sharp revaluation as investors responded to improving fundamentals.

    Nov 2·4 min
    IDEXX Laboratories, Inc. (IDXX) jumps on earnings beats
    IDXX

    IDEXX Laboratories, Inc. (IDXX) jumps on earnings beats

    IDEXX Laboratories, Inc. (IDXX) jumps 18.3% after reporting earnings beats, with investors reacting positively to stronger-than-expected results and improved outlook signals.

    Nov 2·2 min